Last reviewed 2026-04-23 · How we verify

anti-IL-2R

anti-IL-2R drugs target the interleukin-2 receptor to prevent T-cell activation.

anti-IL-2R drugs target the interleukin-2 receptor to prevent T-cell activation. Used for Prevention of organ rejection in kidney transplant recipients.

At a glance

Mechanism of action

By binding to the interleukin-2 receptor, anti-IL-2R drugs inhibit the activation of T-cells, which play a key role in the immune response. This mechanism is particularly useful in treating autoimmune diseases and preventing transplant rejection.

Approved indications

• Prevention of organ rejection in kidney transplant recipients

Common side effects

• Increased risk of infections

Key clinical trials

• REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy (PHASE1)
• Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation (PHASE3)
• Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma (PHASE2)
• Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (PHASE2)
• A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure (PHASE2)
• Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (PHASE2)
• ANTI-TAC THERAPY FOR UVEITIS (PHASE1)
• Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.